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Abstract
Background: Latent autoimmune diabetes in adults [LADA] is a type 1 diabetes that is slowly
developing. This means many people are treated as having type 2 diabetes at diagnosis as they are
adults who are not immediately insulin dependent. LADA can be distinguished from type 2 diabetes
by antibody tests. Patients who are antibody positive have an autoimmune reaction which is similar
to that of type 1 diabetes and is not found in type 2 diabetes. We would like to examine the best
way of treating LADA in the early phase of the conditions, with tablets (similar to type 2 diabetes)
or with insulin (similar to type 1 diabetes).
Methods/design: This is an open parallel group prospective randomised trial. Participants need
to have a GAD antibody test results of 101 WHO units or more and a diagnosis of diabetes not
requiring insulin at diagnosis. Participants will need to have been diagnosed within 12 months and
not treated with insulin at study entry. They will be randomised to receive either insulin (NovoMix
30) or tablets (diet treated followed by metformin followed by glitazone (with or without
metformin) followed by insulin). Primary outcome assessment will be for change in HbA1c and
change in fasting C-peptide over 24 months. Secondary outcome measures will include Quality of
life, GAD antibody levels, adverse events, inflammatory markers, insulin resistance, and markers of
the metabolic syndrome.
Discussion: This study seeks the best treatment for early LADA in terms of maintaining glycaemic
control and maintaining natural insulin production.
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Background
Type 1 diabetes
Diabetes mellitus is the most common endocrine disease.
There are two main types of diabetes, type 1 and type 2.
Although type 1 diabetes often develops in young people,
it can occur at any age. Type 1 diabetes is caused by an
autoimmune process resulting in a selective destruction of
the pancreatic insulin-secreting β-cells. The destruction of
β-cells leads to hyperglycaemia due to a lack of insulin.
The immune changes are reflected by the presence of islet
cell antibodies (ICA) and antibodies to glutamic acid
decarboxylase (GAD) [1]
Type 2 diabetes
Type 2 diabetes most often develops in adults and is char-
acterized by insulin resistance and subsequent insulin
deficiency. Approximately 10% of patients with type 2
diabetes have antibodies to GAD and/or ICA and progress
to insulin dependency [2,3]. The term LADA (latent
autoimmune diabetes in adults) has been introduced to
define adult diabetes patients who are initially non-insu-
lin-requiring but with immune markers of type 1 diabetes,
who progress to insulin dependency.
LADA
Latent autoimmune diabetes in adults is a type 1 diabetes
which shows slow progression to insulin dependence
instead of acute onset as is seen in 'classical' type 1 diabe-
tes. It is an autoimmune condition unlike type 2 diabetes
and therefore can be distinguished from type 2 by blood
tests for antibodies.
Treatment
Early studies in Japan (n = 58) [4-6] have suggested that
LADA patients should start insulin within 1 year of diag-
nosis in order to maintain near normoglycemic control. It
is also suggested that this treatment can prevent slowly
progressive beta-cell failure. Patients taking insulin had an
improved C-peptide response (i.e. improved Beta cell
function and natural insulin production), stable HbA1c
values and reduced auto-antibody level.
However, oral agents such as glitazones have anti-inflam-
matory activity and could potentially also be an effective
treatment for patients in the non-insulin dependent stage
of their diabetes. Rosiglitazone given in combination with
insulin was found to maintain C-peptide levels better
than insulin alone [7]. Laboratory studies support an anti-
inflammatory role for glitazones which could be benefi-
cial for people with LADA [8].
Sulphonylurea treatment may be harmful to people with
LADA as they may deplete the already low reserves of insu-
lin. In some studies, LADA patients given sulphonylurea
(with or without insulin) have persistent antibodies and
poor fasting glucose concentrations compared to people
on insulin alone [5,9,10]
The team at the School of Medicine in Swansea University
[SB, HD and RW] have undertaken a Cochrane systematic
review to examine interventions for LADA [11] which
found that sulphonylurea should not be used in LADA
but there is no significant evidence for or against other
lines of treatment of LADA. To date there are no other sys-
tematic reviews.
Methods/design
Aims and objectives
To compare the effectiveness of treatment regimes for type
1 diabetes compared to regimes for type 2 diabetes in
LADA.
Primary objectives
To examine the effect of standard treatment for type 1
(insulin [NovoMix 30] therapy) compared with standard
treatment for type 2 diabetes (tablets), on (1) change in
fasting serum C-peptide level over 24 months and (2)
change in HbA1c level over 24 months in patients with
LADA.
Secondary objectives
To assess the effect of standard type 1 treatment (insulin)
on average number of times the fasting plasma glucose
level is above 8 mmol/l (141 mg/dl), quality of life
[ADDQol [12]], proportion of patients with insulin
dependence (as judged by C peptide level below 0.38 ng/
ml [13]), GAD antibody level, HOMA, hypoglycaemic
events (particularly hypoglycaemic events), weight/blood
pressure/total cholesterol and inflammatory markers in
LADA patients compared to standard type 2 diabetes treat-
ment.
Design
This trial is a multi-centre open parallel group prospective
randomised trial. Participants are recruited from their pri-
mary health care practitioner following a routine test for
GAD antibodies. They are seen in secondary care at 3 cen-
tres in Wales (Swansea, Carmarthenshire and Cardiff).
The protocol has been approved by the Multi-Centre
Research Ethics Committee for Wales. Each recruited sub-
ject has to sign a consent form and give their consent to
randomisation.
Intervention
Insulin arm: Patients will be given advice on diet and exer-
cise and life style and will be started on NovoMix 30, one
dose of 6 U at the evening/main meal. Dose will be
adjusted in increments of 2–6 U depending on fasting glu-
cose level [See Figure 1]. When total dose equals 16 U
patient will be started on 4 units with breakfast and con-BMC Endocrine Disorders 2008, 8:8 http://www.biomedcentral.com/1472-6823/8/8
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tinue with 16 units with evening meal. Breakfast and/or
evening meal dose will be adjusted where necessary at
increments of 2–6 U depending on fasting and/or pre-
evening meal glucose level. [See Figure 1 below]. Patient
needs to keep a daily diary of insulin doses taken.
All patients will see a dietician before insulin treatment is
initiated. Patients will be contacted weekly by phone in
the first month, fortnightly in the second month and once
a month thereafter. Patients will monitor their blood glu-
cose twice a day for 3 days of the week.
Tablet arm:
[Figure 2] Step 1
Patient's not treated with tablets will be given a 3 months
trial of lifestyle modification including advice on diet,
exercise and smoking. If HbA1c remains at 7% or above
the patient will progress to step 2. Patients will be pro-
gressed to step 2 if their GP has already put them on met-
formin (put in at number of metformin tables that GP has
recommended) or sulphonylurea or if their baseline
HbA1c is above 8% (patients will start on one 500 mg tab-
let per day). This means that sulphonylurea will be dis-
continued in all patients. Patients on step 1 will be
progressed to step 2 before the 3 month period if they
have already had a 3 month period of diet before starting
the study AND during phone contact they report to be
symptomatic (thirst, fatigue, polyuria) and unwell. In
these cases, patients may be invited to attend clinic before
the 3 month period to be given metformin.
Step 2
Life style modification and Metformin. If the patient has a
HbA1c of 7%–7.5% they start on 500 mg × 1 per day for
the next 3 months. If the HbA1c is 7.6%–8.0% they would
start the first week on 500 mg × 1 day and then for the
remaining period of the three months will take 500 mg ×
2 day. If the HbA1c is above 8.0% then patient will be on
500 mg × 3 per day. This will be titrated at the rate of 500
mg × 1 for the first week, 500 mg × 2 for the second week
and 500 mg × 3 for the remaining time of the 3 month
period. If unable to tolerate metformin then the partici-
pant will be given Glucophage SR and if unable to toller-
ate this they will then progress to Step 3. If HbA1c remains
at 7% or above then those on 1 tablet per day will be
moved to 2 tablets per day, those on 2 tablets per day will
be moved to 3 tablets per day, those on 3 tablets per day
will be move to maximum dose of 2 gms per day. If after
3 months the HbA1c is above 7% even with maximum
dose, then progress to Step 3. If during telephone contact
the patient report symptoms then they may be titrated up.
In summary, patients will be have their HbA1c evaluated
every 3 months and will be titriated accordingly.
Insulin treatment Figure 1
Insulin treatment.
Adjust dose of NovoMix 30 once a week: 
Fasting or pre-evening meal glucose  Adjustment of breakfast and/or evening meal dose (i.e. 
evening dose for pre-breakfast glucose and morning dose 
for pre evening meal glucose) 
Mmol/l    
<3.0 or severe hypoglycemia    -4 U 
3.1-4.4   -2U 
4.5-6.0   No  change
6.1-7.8   +2U 
7.9-10.0   +4U 
>10.0   +6U BMC Endocrine Disorders 2008, 8:8 http://www.biomedcentral.com/1472-6823/8/8
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Step 3
Life style modification and Glitazone [Rosiglitazone].
Patients with a HbA1c of 7% or above will be given 4 mg
once per day for 3 months. If after a 3 month period the
HbA1c remains at 7% or above then titrate to maximal
dose of 4 mg twice per day with or without Metformin. If
HbA1cremains at 7% or above for an additional 3 months
then move to step 4. Therefore, glitazone monotherapy
will be used if Metformin intolerant otherwise glitazone
will be added to the metformin (as per standard practice).
Before initiation of Rosiglitazone a repeat medical history
will be taken with special emphasis on cardiovascular dis-
ease, if patients have a history of cardiovascular disease
(defined as IHD, PVD) they will not be initiated on Ros-
iglitazone but will move directly to Step 4 (insulin).
Patients on rosiglitazone will be monitored using the
adverse events form, for symptoms of heart disease specif-
ically for chest pain and shortness of breath. Any adverse
events suggestive of heart disease will result in Rosiglita-
zone being discontinued and the patient moving to step 4.
Step 4
Life style modification and insulin therapy (oral agents
will be stopped). Titration will be based on fasting blood
glucose level (as given in Figure 1). The initiation of insu-
lin will the same as for the insulin arm and will follow the
protocol detailed above.
All tablet treated patients will be asked to keep a diary of
daily medication and record blood glucose levels weekly.
All changes in medication will be notified to the patients
GP.
Study population and inclusion/exclusion criteria
Subject are recruited from their primary care practitioner
if they have a diagnosis of diabetes with a GAD antibody
result of 101 WHO units or more.
Inclusion criteria
1. Male, non-fertile female (i.e., post menopausal, post
hysterectomy, or sterilized by tubal ligation) or female of
childbearing potential using a medically approved birth
control method.
2. The patient has a diagnosis of diabetes mellitus accord-
ing to WHO classification.
3. The patient has a positive GAD antibody test of 101
WHO units or more on two separate occasions.
Standard treatment arm Figure 2
Standard treatment arm.
Time point 
Baseline                 Entry Treatment                                 HbA1c                                               Action  
                                                                                          <7%                                                    No change 
                               Diet                                                      >7%                                                   1 tb Meformin (if HbA1c is 7%-7.5%) 
                                                                                                                                                      2 tbs Meformin (if HbA1c is 7.6%-8.0%)           
                                                                                                                                                      3 tbs meformin (If HbA1c is 8%+) 
                              Meformin                                           <7%                                                      No change 
                                                                                        >7%                                                      Increase by 1 tb (if Meformin dose 1-3tbs) 
                                                                                                                                                      Add 4 mg Rosiglitazone (if Meformin 4 tbs) 
                        Sulphonylurea                                        <7%                                                     Sulphonylurea discontinued. 1 tb Metformin 
                                                                                        >7%                                                     Sulphonylurea discontinued. 2 tbs Meformin BMC Endocrine Disorders 2008, 8:8 http://www.biomedcentral.com/1472-6823/8/8
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4. Age 18 +
5. The patient did not start on insulin within 1 month of
diagnosis
6. Written informed consent to participate in the study.
7. Ability to comply with all study requirements.
Exclusion criteria
1. Pregnant or breast-feeding females and females who
plan pregnancy or breast-feeding during the course of the
study.
2. A history of:
▪ Diabetes that is a result of pancreatic injury, or secondary
forms of diabetes, e.g., Cushing's syndrome and acromeg-
aly.
▪ Acute metabolic diabetic complications such as ketoaci-
dosis or hyperosmolar state (coma) within the past 6
months
3. Acute infections, which may affect blood glucose con-
trol within 4 weeks prior to visit 1.
4. Malignancy including leukaemia and lymphoma (not
including basal cell skin cancer) within the last 5 years.
5. The patient has a known immune deficiency from any
disease, or a condition associated with an immune defi-
ciency.
6. The patient is receiving immunosuppressive or immu-
nomodulating agents or cytotoxic therapy, or any medica-
tion that, in the opinion of the site investigator, might
interfere with the study.
7. Any of the following significant laboratory abnormali-
ties:
￿ Patients with severe renal failure as defined previous
renal transplant or currently having renal dialysis or GFR
< 30.
￿ Clinically significant laboratory abnormalities, con-
firmed by repeat measurement, that may interfere with
the assessment of safety and/or efficacy of the study drug,
other than hyperglycemia and glycosuria at visit 1.
￿ Severe ketonuria (+++ on urine sticks testing; ++ on
repeated urine sticks testing).
8. The patient is a known or suspected drug abuser.
9. The patient has chronic hepatitis or liver cirrhosis, or
any other chronic liver disease.
10. The patient is known to test positive for hepatitis B
antigens or hepatitis C antibodies
11. The patient is known to test positive for HIV antibod-
ies.
12. The patient has any significant diseases or conditions,
including psychiatric disorders and substance abuse that,
in the opinion of the site investigator, are likely to affect
the patient's response to treatment or their ability to com-
plete the study.
13. The patient has chronic haematological disease.
14. The patient has had a severe blood loss (≥ 400 mL,
e.g., blood donation) within 2 months before the first
dosing of the study medication.
15. The patient has known proliferative retinopathy.
16. Patient has had stage 3–4 heart failure.
17. The patient is participating in another research study
which may affect the results of this trial.
Withdrawn from study
A patient is considered to have withdrawn from the study
if they completely withdraw from the study, i.e.:
- Move and do not provide a new address or contact
number
- Miss more than 3 visits without contacting the study cen-
tre.
- Die
However, if they discontinue treatment but continue par-
ticipate in data collection they will not be considered to
have withdrawn, i.e:
- Want to change therapy due to personal reasons but
attend a termination visit.
- Experience a serious adverse event that in the medical
judgement of the site investigator and for the best interest
of the subject, are grounds for discontinuation, but attend
a termination visit.
- Withdraw consent but give consent to the use of the data
collected to date.BMC Endocrine Disorders 2008, 8:8 http://www.biomedcentral.com/1472-6823/8/8
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- Develop a concomitant condition which is given in the
exclusion criteria but do attend a termination visit.
If a patient discontinues the study prematurely at any time
after entering the study, attempts should be made to con-
duct a termination final visit at which time all of the
assessments listed for the final visit will be performed.
The reason for premature discontinuation and – if appli-
cable – the final visit will be documented.
Follow up procedure
Patients are seen for a screening visit where they are asked
to give consent and have baseline tests regarding inclu-
sion/exclusion criteria. They return after 2 weeks for ran-
domisation and are followed every 3 months there after.
[See Figure 3]
Analysis plan
The statistical evaluation will be performed using SPSS.
All data will be listed and trial summary tables will be pro-
vided. Summary statistics will be presented by group.
The primary analysis will be an intention to treat analysis
examining (1) the average change in C peptide level at the
end of the study in both groups and (2) the average
change in HbA1c level at the end of the study in both
groups. A linear regression model will be used to examine
the effect of baseline GAD level, age, sex and baseline fast-
ing C-peptide or HbA1c level as covariate and a treatment
term on the change in HbA1c and C-peptide levels. In
addition, repeated measures analysis (area under the
curve, maximum minus minimum, time taken to maxi-
mum, time taken to minimum and slope) for C-peptide
and HbA1c will be performed. ANOVA for repeated meas-
urements with be used when variables are normally dis-
tributed. Otherwise, log transformations or non
parametric tests will be employed.
Data will be collected by research nurses under the medi-
cal care of Professor Stephen Bain and Dr Jeffrey Stephens
and monitored by the trial co-ordinator. The analysis will
be performed by Dr Wai-yee Cheung who will be blind to
treatment group until after all analysis has been com-
pleted and interpreted. The CONSORT statement will be
followed and used for reporting results.
Secondary analysis will include: Intention to treat analysis
of :
(1) Average change in fasting C-peptide level in the insu-
lin group compared to the control (best alternative care)
group at 12 months.
(2) Average change in HbA1c level in the insulin group
compared to the standard care group at 12 month. Data
will be presented using confidence intervals only.
(4) Quality of life in the insulin vs standard care groups
(5) Number of events of fasting glucose being above 8 in
the insulin vs standard care arm.
(6) Proportion of patients with a C-peptide below 0.38
ng/ml at baseline, 12 months and 24 months.
(7) Level of inflammatory markers in the insulin vs stand-
ard care arm
(8) GAD levels of insulin vs standard care
(9) Episodes of adverse events in the insulin vs standard
care arms
(10) Weight gain in terms of BMI and waist/hip ratio in
both groups
(11) HOMA or insulin resistance in both groups
We shall use two sided tests and confidence intervals for
all comparisons.
Handling of missing and incomplete data
Data may or may not be missing at random. We shall
compare patients with complete and missing data in sex,
age and metabolic control (HbA1c) to test whether data
are missing at random.
If data are missing at random and a participant does not
attend follow-up visits, then the last recorded measure
will be used as the final value. In cases were laboratory
data is missing we will attempt to obtain values from the
participants laboratory records supplied to their GP
(using their NHS number in the diagnostics laboratory)
unless they have actively withdrawn their consent for us to
view their GP records.
If data are missing in a non-random way we shall compare
the 'worst' case (high HbA1c and low c-peptide) and the
'best' case (normal HbA1c and normal c-peptide) to esti-
mate confidence intervals for the final analysis.
Sample size
The study conducted in China [14] examined fasting C-
peptide levels over 12 month, the average difference in C-
peptide at 12 months was 0.18 nmol/l (stdev: 0.5 nmol/l)
between the insulin vs the SU groups. To find a difference
of 0.7% in average HbA1c (standard deviation = 1.5%) we
would need 97 analysible people in the insulin and theBMC Endocrine Disorders 2008, 8:8 http://www.biomedcentral.com/1472-6823/8/8
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Schedule of visits Figure 3
Schedule of visits.
Visit  Screening Medication  3 4 5 6 7 8 9 10 11
Months (from 
medication) 
0 0 1 3 6 9 12 15 18 21 24
Medical  History  X               
Information about 
insulin 
  X             
Informed Consent   X                     
Randomization   X             
Screening  tests*  X               
BP, W/H ratio, 
cholesterol 
X      X X X X
Dietician            X     
Height  X               
Weight  X    X  X X X  X  X X X  X 
Serum or Urine 
Pregnancy Test, if 
indicated  
X  X  X  X X X  X  X X X  X 
Collection of diary      X  X  X  X  X  X  X  X  X 
HOMA    X        X    X 
HBA1c  X      X X X  X  X X X  X 
Fasting  Glucose   X        X    X 
Fasting  C-peptide    X        X    X 
Adverse  Events      X  X X X  X  X X X  X 
Co-medication  X  X  X  X X X  X  X X X  X 
Co-disorders  X  X  X  X X X  X  X X X  X 
GAD Autoantibodies  X          X    X 
Quality of Life    X      X    X    X    X 
Inflammatory markers 
[Il-6, CRP] 
X      X X X X
FBC, U&E, Liver 
function test 
X          X    X 
*Creatinine, appointment for eye examination, dip stick for Ketonuria.BMC Endocrine Disorders 2008, 8:8 http://www.biomedcentral.com/1472-6823/8/8
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standard care arms of the study (power 90%, significance
= 5%). This would detect an average difference of 0.2
nmol/l in fasting C-peptide. As the power calculation is
based on patients in China, we will re-calculate the sam-
ple size based on the standard deviation of the first 30
patients recruited in our study. We will examine the stand-
ard deviation of the HbA1c and the fasting C-peptide in
all 30 patients at 3 months (regardless of treatment) in
order to re-estimate the sample size assuming a difference
of 0.7% in HbA1c and 0.2 nmol/l in fasting C-peptide.
Randomisation procedure
WYC will provide SB with a randomisation sequence from
a computer randomisation programme [15]. The clinical
nurse (KR) will see the patients and register their details
on the registration database, before seeking their random
allocation from SB.
Randomisation procedure: The randomisation sequence
will be determined by a computer randomisation pro-
gramme [15]
Discussion
Within this study we introduce routine GADA testing at
the general practice level for all newly people with diabe-
tes. We provide newsletters, an internet site http://
www.locallada.swan.ac.uk and a helpline for people diag-
nosed with LADA. This is the first study in Europe exam-
ining the best first line treatment at the primary care level
for the early management of people with LADA.
Abbreviations
LADA: Latent autoimmune diabetes in adults; GAD:
Glutamic Acid Decarboxylase; ICA: islet cell antibodies;
HOMA: Homeostasis Model Assessment.
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